ARMATA PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.76 USD | +9.06% |
|
+3.56% | -14.81% |
| Mar. 21 | Earnings Flash (ARMP) ARMATA PHARMACEUTICALS Reports Q4 Revenue $1.5M | MT |
| Mar. 21 | Armata Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Evolution of the average Target Price on Armata Pharmaceuticals, Inc.
Price target over the last 5 years
History of analyst recommendation changes
5a471357996a845c.T90MRcqWRUty6fC8werRLl_THRP7lRNJ6wsuxXVCqN4.CeVGd_ygcQwomZLwtoigQS-7ZHCX5GQQrF9MkxQT5Z8HmDgK8-chHBujvQ~d83de35ad58d950384a3b3796f76513e
Analysts' Consensus
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.76
USD
Average target price
8
USD
Spread / Average Target
+189.86%
High Price Target
9
USD
Spread / Highest target
+226.09%
Low Price Target
7
USD
Spread / Lowest Target
+153.62%
Consensus detail
Consensus revision (last 18 months)
Analysts covering Armata Pharmaceuticals, Inc.
| HC Wainwright |
Trading Rating
Investor Rating
ESG Refinitiv
EPS Revisions
- Stock Market
- Equities
- ARMP Stock
- Consensus Armata Pharmaceuticals, Inc.
